MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Metrics to compare | MDWD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMDWDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.5x | 10.9x | −0.5x | |
PEG Ratio | −0.31 | 0.15 | 0.00 | |
Price/Book | 5.2x | 1.1x | 2.6x | |
Price / LTM Sales | 13.4x | 2.0x | 3.2x | |
Upside (Analyst Target) | 77.8% | 198.5% | 44.2% | |
Fair Value Upside | Unlock | 28.0% | 5.5% | Unlock |